• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Potthoff named president, CEO of Theorem Clinical Research

Potthoff named president, CEO of Theorem Clinical Research

November 2, 2011
CenterWatch Staff

John Potthoff has stepped down as chief operating officer of CRO INC Research to become president and CEO of Theorem Clinical Research, succeeding James Pusey, who now becomes Theorem’s executive chairman to the board of directors.

Potthoff came to INC when Tanistry, a CNS-focused CRO he founded, was bought by the company. During his time at INC, Potthoff led CNS therapeutics, global business development and clinical development in North America. Prior to founding Tanistry and serving as its president and CEO, Potthoff spent seven years with PPD.

Theorem is the new company formed when publicly-traded Omnicare spun off its CRO holdings, selling them to equity investment firm Nautic Partners in April 2011. Pusey became president and CEO of the Omnicare CRO in 2009, tasked with fixing the ailing division and transitioning it through its spin off and sale. Before that, he had turned around MDS Pharma Services’ late-phase CRO operations, which were then sold to INC. 


Theorem has about 900 employees, and in the last nine months has seen a significant increase in backlog, with the majority of growth in North America and Asia Pacific, as well as in the CRO’s technical services and medical device business units, Pusey said in a release.

--Suz Redfearn

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing